| CNC |
Report |
Q2 2026 Adjusted EPS |
BEAT |
pred ~$0.97 vs. cons $0.89 |
MEDIUM |
| CNC |
Report |
Medicaid HBR (Q2) |
BEAT |
pred ~93.2% vs. cons 93.6% (lower HBR = better) |
MEDIUM |
| CNC |
Report |
Marketplace/Commercial HBR (Q2) |
MISS |
pred ~76.2% vs. cons 75.3% (higher HBR = worse), reflecting continued Silver-tier acuity pressure flagged by peers (Molina, Elevance) |
LOW |
| CNC |
Guide |
FY2026 Adjusted EPS floor guidance |
BETTER |
guide ~>$3.55 vs. cons $3.44 (FY2026) |
MEDIUM |
| CNC |
Guide |
Marketplace full-year pretax margin assumption |
UNCHANGED |
guide ~3.0% vs. cons ~3.3-3.5% bull-case expectation for an upgrade (FY2026) |
LOW |
| CNC |
Guide |
Marketplace year-end membership guide |
UNCHANGED |
guide ~3.0M vs. cons ~3.05-3.1M (FY2026 exit) |
MEDIUM |
| CNC |
Return |
Day-1 residual (stock − beta × S&P 500) |
-4.0% |
— |
MEDIUM |
| CNC |
Return |
5-day cumulative residual |
-6.0% (FOLLOW-THROUGH) |
CNC enters the print near/above average analyst price targets after a ~90%+ rally off April lows, leaving little room for anything short of a clearly quantified, sector-corroborating Marketplace risk-adjustment win. Peer reads this cycle (Molina's ACA membership collapse and 'underestimated' pricing miss, Elevance's beat-but-punished modest raise) suggest the market has turned skeptical of vague Marketplace commentary even alongside a headline EPS beat and FY floor raise. If management confirms only the already-embedded ~3% Marketplace margin without a hard receivable number, sell-side analysts likely trim out-quarter/2027 Marketplace and MA-breakeven assumptions even as they nudge FY26 EPS up on Medicaid/Medicare strength, producing a fade in Day-1 optimism (if any) and a mild continued drift lower into the print's aftermath rather than a sharp reversal, since the core Medicaid/Medicare trend story remains intact. |
LOW |